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Case report
Concomitant endometrioid carcinoma of the
ovary and endometrial carcinoma of the
uterus associated with adenocarcinoma
in situ of the cervix
M Parker, R Wallace, D Allen
Accepted 18 July 1989.
Endometrioid carcinoma of the ovary is the third most common epithelial
tumour of the ovary, accounting for between 16% and 25% of these tumours.1
A co -existing adenocarcinoma of the endometrium has been found in 14-25%
of patients.2' 3
CASE REPORT
A 45-year-old female, para 2, presented to the gynaecological outpatient clinic
with a two-year history of menorrhagia. There was no intermenstrual or post-
coital bleeding. General examination was satisfactory apart from obesity (94kg).
Vaginal examination revealed a slightly enlarged anteverted uterus with no
obvious adnexal masses. The cervix appeared healthy. Haematological investig-
ations were normal with no evidence of anaemia. A diagnostic curettage was
performed and the histological examination showed adenomatous hyperplasia
with no evidence of cellular atypia or malignancy. Following dietary advice the
patient lost 18kg weight. She was then admitted for an abdominal total
hysterectomy because of continuing menorrhagia, further curettage six months
after the initial curettage having shown adenomatous hyperplasia. At operation,
the right ovary was unexpectedly enlarged (10cm diameter), multilocular with
solid and cystic areas. The uterus was bulky but otherwise appeared normal.
Abdominal total hysterectomy and bilateral salpingo -oophorectomy was
performed. There was no evidence of metastatic disease in the omentum, liver or
bowel.
Histological examination of the right ovary showed a primary endometrioid
adenocarcinoma. It was partially necrotic and moderately well differentiated. It
had focally infiltrated the inner aspect of the capsule and residual ovarian cortex.
The serosa was not involved. In the endometrial cavity there was a secretory
phase endometrium and at one point a small focus of well differentiated
adenocarcinoma. It had not infiltrated the myometrium. (The previous curettage
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biopsy specimen was reviewed and confirmed as showing only adenomatous
hyperplasia with some squamous metaplasia). In the uterine cervix the surface
and crypt endocervical epithelium showed a combination of tubal metaplasia
and adenocarcinoma in situ. This neoplastic epithelium had differentiated along
endometrial lines. There was no invasive malignancy. The fallopian tubes did not
show any significant abnormality and the left ovary contained a haemorrhagic
corpus luteum.
There were no postoperative complications and she was discharged home to start
a first course of chemotherapy with cisplatin (cis-diamminedichloro-platinum).
COMMENT
Ovarian epithelial neoplasms exhibit aspectrum ofMullerian differentiation which
includes an endometrioid pattern. The two commonest ovarian carcinomas are
serous and mucinous cystadenocarcinomas. Women with endometrioid tumours
of the ovary have a relatively favourable prognosis, a five-year survival rate
varying between 40% and 70%,1 2 compared with 26% for serous cystadeno
carcinoma.4 The presence of a co-existing adenocarcinoma of the endometrium
with endometrioid carcinoma is a relatively common finding, occurring in
14-25% of patients2 3 and the concomitant endometrial carcinoma is not
detrimental to the prognosis.5 Women with concomitant tumours were thought
to present at an earlier age than expected for either ovarian or endometrial
carcinoma 2,5 although this is now disputed. It has been shown in a recent study
that there was no significant difference in age or menopausal status between the
women who presented with an ovarian lesion only and those who presented with
concomitant tumours.5 Inthe present casethe patient was youngerthan expected
for either ovarian or endometrial carcinoma.
Alkylating agents have been the cornerstone of chemotherapeutic treatment of
advanced epithelial ovarian cancer since 1952, when Rundles and Burton
reported that triethylene melamine produced a favourable response in about
30% of patients with advanced ovarian cancer.7 Since the demonstration of
significant activity of cis -diamminedichloroplatinum (cis -platin) against epithelial
ovarian cancer in 1976,8 this drug has now become the most important agent in
the treatment of ovarian cancer.
To our knowledge, this report is the first to describe adenocarcinoma in situ ofthe
cervix in association with both endometrioid carcinoma of the ovary and adeno-
carcinoma of the endometrium. It is a very unusual case of multifocal malignant
field change in the Mullerian epithelium along endometrial lines. It highlights the
possibility of concurrent disease in developmentally linked but anatomically
distinct sites and serves to emphasise the need for an integrated approach to
gynaecological assessment in these patients.
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